TNF inhibition in SLE: where do we stand?

1 Isenberg D  Rahman A  . Systemic lupus erythematosus–2005 annus mirabilis. Nat Clin Pract Rheumatol 2006; 2: 145–152.

2 Anolik JH  Aringer M  . New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005; 19: 859–878.

3 Strand V  . Lessons learned from clinical trials in SLE. Autoimmun Rev 2007; 6: 209–214.

4 Charles PJ  Smeenk RJ  De Jong J  Feldmann M  Maini RN  . Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383–2390.

5 De Rycke L  Kruithof E  Van Damme N  . Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48: 1015–1023.

6 Eriksson C  Engstrand S  Sundqvist KG  Rantapaa-Dahlqvist S  . Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64: 403–407.

7 Ferraro-Peyret C  Coury F  Tebib JG  Bienvenu J  Fabien N  . Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6: R535–R543.

8 Allanore Y  Sellam J  Batteux F  Job DC  Weill B  Kahan A  . Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004; 22: 756–758.

9 Ferraccioli GF  Assaloni R  Di Poi E  Gremese E  De Marchi G  Fabris M  . Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology (Oxford) 2002; 41: 1109–1112.

10 Jacob CO  McDevitt HO  . Tumour necrosis factor-alpha in murine autoimmune ‘lupus’ nephritis. Nature 1988; 331: 356–358.

11 Gordon C  Ranges GE  Greenspan JS  Wofsy D  . Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989; 52: 421–434.

12 Kontoyiannis D  Kollias G  . Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000; 30: 2038–2047.

13 Aringer M  Smolen JS  . TNF and other proinflammatory cytokines in SLE: a rationale for therapeutic intervention. Lupus 2004; 13: 344–347.

14 De Rycke L  Baeten D  Kruithof E  Van Den BF  Veys EM  de Keyser KF  . The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005; 14: 931–937.

15 Aringer M  Smolen JS  . The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202.

16 Studnicka-Benke A  Steiner G  Petera P  Smolen JS  . Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067–1074.

17 Aringer M  Smolen JS  . Cytokine expression in lupus kidneys. Lupus 2005; 14: 13–18.

18 Zampieri S  Alaibac M  Iaccarino L  . Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006; 65: 545–548.

19 De Bandt M  Sibilia J  Le Loët X  . Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545–R551.

20 Aringer M  Steiner G  Graninger WB  Hofler E  Steiner CW  Smolen JS  . Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274–279.

21 Aringer M  Houssiau F  Graninger WB  Feierl E  Steiner G  Smolen JS  . Long term safety and efficacy of open-label infliximab for SLE. Ann Rheum Dis 2007; 66: 455.

22 Cervera R  Khamashta MA  Font J  . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299–308.

23 Kang I  Park SH  . Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15: 528–534.

24 Keane J  Gershon S  Wise RP  . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098–1104.

25 Lee JH  Slifman NR  Gershon SK  . Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565–2570.

26 Slifman NR  Gershon SK  Lee JH  Edwards ET  Braun MM  . Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319–324.

27 Aringer M  Graninger WB  Steiner G  Smolen JS  . Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161–3169.

28 Katz RS  Holt-Daly N  MacDonald PA  . Frequent infusion reactions associated with infliximab treatment in patients with polyarthritis related to systemic lupus erythematosus. Arthritis Rheum 2003; 48: S379.

29 Bernatsky S  Ramsey-Goldman R  Isenberg D  . Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46: 830–832.

30 Zintzaras E  Voulgarelis M  Moutsopoulos HM  . The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337–2344.

31 Thonhofer R  Gaugg M  Kriessmayr M  Neumann HJ  Erlacher L  . Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 2005; 64: 1098–1099.

32 Mackey AC  Green L  Liang LC  Dinndorf P  Avigan M  . Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265–267.

33 Wegener's Granulomatosis Etanercept Trial (WGET) Research Group . Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351–361.

34 Principi M  Di LA  Ingrosso M  . Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report. Immunopharmacol Immunotoxicol 2004; 26: 243–248.

35 Hayat SJ  Uppal SS  Narayanan Nampoory MR  Johny KV  Gupta R  Al-Oun M  . Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol 2007; 26: 973–975.

36 Henzan T  Nagafuji K  Tsukamoto H  . Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 2006; 81: 59–61.

37 Ideguchi H  Ohno S  Takase K  . Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology (Oxford) 2007; 46: 1621–1622.

38 Takahashi N  Naniwa T  Banno S  . Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 2008; 18: 72–75.

39 Norman R  Greenberg RG  Jackson JM  . Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006; 54: S139–S142.

40 Hiepe F  Bruns A  Feist E  Burmester GR  . Successful treatment of a patient suffering from a refractory subacute cutaneous lupus erythematosus (SCLE) with blockers of tumour necrosis factor a. Arthritis Rheum 2004; 50: S413.